A Assateerawatts

Learn More
A comparative study was conducted to evaluate the immunogenicity of hepatitis B vaccine in low and normal birth weight infants. Hepatitis B vaccine (Hevac B Pasteur) was given to 50 low birth weight infants and 50 controls, matched by sex and date of delivery. The vaccine was given at birth, 1, 2 and 12 months of age. HBsAg and anti-HBs were assessed at(More)
A reduced dose of plasma derived hepatitis B vaccine (Hevac B) was tested for efficacy in the prevention of perinatal hepatitis B virus (HBV) transmission in high risk neonates born from e-antigen positive HBsAg carrier mothers. Forty newborn infants born of these mothers were given hepatitis B immune globulin (HBIG) 100 IU intramuscularly immediately after(More)
In areas with high carrier rates for hepatitis B the combination of hepatitis B immune globulin and hepatitis B vaccine prevent perinatal infection in 90-95% of the newborn infants. Since 1979 the failure of perinatal prevention of hepatitis B infection was observed in only two cases. Evidence of intrauterine infection is presented in these two cases.
The vertical transmission of the hepatitis B surface antigen (HBsAG) from HBsAg carrier mothers to their infants and children were studied in 42 mother-infant pairs, 27 siblings aged under 5 years and 34 fathers of these families. Thirteen out of 42 (30.9%) infants born from these mothers became HBsAg carriers at 3 to 6 months of age. Vertical transmission(More)
The efficacy of hepatitis B virus vaccine to prevent the vertical transmission of hepatitis B virus (HBV) in infants born to HBsAg carrier mothers was assessed in 20 mother-infant pairs. A dose of 10 micrograms of HBV vaccine was injected intramuscularly at 0, 30 and 180 days after birth to newborn infants. Neither local nor systemic reaction was observed(More)
Combined prophylaxis of perinatal transmission of hepatitis B virus (HBV) with hepatitis-B immunoglobulin (HBIG) and hepatitis-B vaccine was investigated in 40 infants born to HBeAg positive carrier mothers. The efficacy of two combined prophylaxis schedules was compared to 78 similar infants in the control group receiving no treatment, by following the HBV(More)
A half dose recombinant hepatitis B vaccine (HBVax II, MSD, 5 micrograms) was investigated for efficacy in the prevention of perinatal hepatitis B virus (HBV) transmission in high risk neonates born from e-antigen positive HBsAg carrier mothers as compared to the half-standard dose regimen of plasma derived hepatitis B vaccine (HBVax, MSD, 10 micrograms).(More)